Matthew Lardy

Statistics

Publications

Citations

H-Index

Active since

2024

Affiliations

Ondine Biopharma (United States)(Current)

Matthew Lardy is an author at Ondine Biopharma (United States) specializing in resistance to targeted therapy, molecular oncology, and cancer genomics.

ORCID

Publications per year

2024–2024

Publications

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations

John Tyhonas, Lee D. Arnold, Jason M. Cox et al. · Journal of Medicinal Chemistry · 2024 · 17 citations · Full text

Medicine, Molecular Medicine, Oncology +16

The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations

Eranga R. Balasooriya, Qibiao Wu, Haley Ellis et al. · Clinical Cancer Research · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17

1–2 of 2